SGLT2 inhibitors can slow progression of chronic kidney disease
Worldwide, 850 million people are affected by chronic kidney disease (CKD)—a worrying figure, and one that continues to rise. Treatment options for patients with CKD are multiple and often determined by the etiology of CKD. So far, RAAS blockade (ACE inhibitors or angiotensin receptor blockers) was one of the most effective therapeutic intervention which has […]
Continue Reading